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Abstract
Background  and  objective:  Sedation  in  dialysis  dependent  end-stage  renal  disease  patients
requires caution  as  a  result  of  performing  high  doses  of  sedatives  and  its  complications.  Mul-
tidrug sedation  regimens  might  be  superior  and  advantage  on  lesser  drug  consumption  and  by
the way  adverse  events  which  occur  easily  in  end-stage  renal  disease  patients.  We  evaluated
the effects  of  dexmedetomidine  premedication  on  propofol  consumption,  sedation  levels  with
Observer’s  Assessment  of  Alertness  and  Sedation  scores  and  the  bispectral  index  and  the  hemo-
dynamic changes,  potential  side  effects  in  geriatric  patients  with  end-stage  renal  disease  who
underwent  hip  fracture  surgery  under  spinal  anesthesia.
Method:  In  this  randomized,  controlled,  double-blind  study  60  elderly  patients  (age  ≥  65  years)
with end-stage  renal  disease  and  hip  fracture  scheduled  for  anterograde  femoral  intramedullary
nailing were  assigned  to  groups  that  received  either  intravenous  saline  infusion  (Group  C)
or dexmedetomidine  0.5  g/kg/10  min  infusion  for  premedication  (Group  D).  All  the  patients
received  propofol  infusion  after  the  induction  of  the  spinal  anesthesia.
Results:  Total  propofol  consumption,  propofol  dose  required  for  targeted  sedation  levels
according  to  Observer’s  Assessment  of  Alertness  and  Sedation  scores  and  bispectral  index  levels,
recovery times  were  signiﬁcantly  lower  in  Group  D  (p  <  0.001).  The  time  to  reach  to  Observer’s
Assessment  of  Alertness  and  Sedation  score  4  and  to  achieve  bispectral  index  ≤  80  was  signi-
ﬁcantly lower  in  Group  C  compared  with  Group  D  (p  <  0.001).  Adverse  events  were  similar  in
both groups.
Conclusion:  Dexmedetomidine  premedication  lowers  intraoperative  propofol  consumption  to
maintain targeted  level  of  sedation.  Therefore  low  dose  dexmedetomidine  premedication  in
addition to  propofol  infusion  might  be  an  alternative  in  geriatric  patients  with  end-stage  renala  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
disease for  sedation.
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PALAVRAS-CHAVE
Paciente  geriátrico;
Doenc¸a  renal  em
estágio  terminal;
Dexmedetomidina;
Propofol
Efeito  da  pré-medicac¸ão com  dose  baixa  de  dexmedetomidina  sobre  o consumo  de
propofol  em  pacientes  geriátricos  com  doenc¸a renal  em  estágio  terminal
Resumo
Justiﬁcativa  e  objetivo:  A  sedac¸ão  em  paciente  dependente  de  diálise  com  doenc¸a  renal  em
estágio terminal  (DRET)  requer  cautela  como  resultado  da  administrac¸ão  de  altas  doses  de  seda-
tivos e  suas  complicac¸ões.  Os  regimes  de  sedac¸ão  com  múltiplas  drogas  podem  ser  superiores  e
vantajosos  em  relac¸ão  ao  consumo  menor  de  drogas  e  aos  eventos  adversos  que  ocorrem  facil-
mente em  pacientes  com  DEET.  Avaliamos  os  efeitos  da  pré-medicac¸ão  com  dexmedetomidina
sobre o  consumo  de  propofol,  os  níveis  de  sedac¸ão  com  os  escores  da  Observer’s  Asssessment
of Alertness  and  Sedation  (OAA/S)  e  do  índice  bispectral  (BIS),  as  alterac¸ões  hemodinâmicas  e
os potenciais  efeitos  colaterais  em  pacientes  geriátricos  com  DRET  submetidos  à  cirurgia  para
fratura de  quadril  sob  raquianestesia.
Método:  Neste  estudo  randômico,  controlado  e  duplo-cego,  60  pacientes  idosos  (idade  ≥  65
anos), com  DRET  e  fratura  de  quadril,  agendados  para  ﬁxac¸ão  intramedular  de  haste  femoral
anterógrada  foram  designados  para  grupos  para  receberam  infusão  intravenosa  de  soluc¸ão  salina
(Grupo C)  ou  pré-medicac¸ão  com  infusão  de  0,5  mg  kg/10  min  de  dexmedetomidina  (DEX)  (Grupo
D). Todos  os  pacientes  receberam  infusão  de  propofol  após  a  induc¸ão  da  raquianestesia.
Resultados:  O  consumo  total  de  propofol,  a  dose  de  propofol  necessária  para  os  níveis-alvo  de
sedac¸ão de  acordo  com  os  escores  da  OAA/S,  os  valores  do  BIS  e  os  tempos  de  recuperac¸ão
foram signiﬁcativamente  menores  no  Grupo  D  (p  <  0,001).  O  tempo  para  atingir  o  escore  4  na
OAA/S e  valores  BIS  ≤  80  foi  signiﬁcativamente  inferior  no  Grupo  C  em  comparac¸ão  com  o  Grupo
D (p  <  0,001).  Os  eventos  adversos  foram  semelhantes  em  ambos  os  grupos.
Conclusão:  A  pré-medicac¸ão  com  dexmedetomidina  reduz  o  consumo  de  propofol  no  intraoper-
atório para  manter  o  nível-alvo  de  sedac¸ão.  Portanto,  a  pré-medicac¸ão  com  DEX  em  dose  baixa
em combinac¸ão  com  infusão  de  propofol  pode  ser  uma  alternativa  para  sedac¸ão  em  pacientes
geriátricos  com  DRET.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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liver  failure,  obesity  (body  mass  index  >  30),  mental  disor-Introduction
The  incidence  of  end  stage  renal  disease  and  dialysis  pop-
ulation  in  the  elderly  continues  to  increase  universally.1--3
Hip  fractures  are  also  major  problem  and  the  anesthesia
technique  should  be  planned  in  detail  due  to  potential  alter-
ations  in  volume  distribution,  protein  binding,  and  drug
metabolism  and  excretion.4--6 In  an  ideal  anesthesia  regime,
the  most  important  parameters  are  providing  hemodynamic
stability  with  optimal  ﬂuid  and  electrolyte  balance,  using
drugs  with  a  lower  metabolism,  shorter  half-life  and  non-
renal  clearance,  targeting  early  recovery  and  return  of
cognitive  and  psychomotor  functions.7
Neuraxial  techniques  such  as  single  spinal  injection  is
frequently  performed  for  the  intraoperative  anesthesia
management  of  patients  with  chronic  renal  failure.8 Coad-
ministration  of  spinal  anesthesia  and  sedation  became  a
standard  protocol  for  providing  patients’  anxiolysis  and
amnesia  at  the  intraoperative  period.9 Propofol  is  the  fre-
quently  used  agent  and  combination  regimens  such  as
propofol  vs  alfentanil  or  midazolam  vs  fentanyl  for  seda-
tion  are  commonly  used  in  patients  with  chronic  renal
failure.10,11 The  sedoanalgesia  drug  doses  should  be  titrated
and  to  reduce  dose  consumption  combination  regimens
should  be  performed  in  hemodialysis  patients.12Dexmedetomidine  (DEX)  is  a  selective  2  receptor  ago-
nist  agent,  might  be  an  alternative  of  choice  for  combination
regimen  with  propofol  due  to  its  sedative  and  analgesic
d
a
hroperties  with  minimal  effects  on  ventilation.13 There  are
imited  number  of  studies  investigating  the  effect  of  DEX
n  patients  with  end  stage  renal  disease  (ESRD),  however
hese  studies  are  not  speciﬁc  to  geriatric  patients  at  the
ame  time.14,15
In  this  study  we  evaluate  the  effects  of  dexmedeto-
idine  premedication  on  propofol  consumption,  sedation
evels,  hemodynamic  changes,  potential  side  effects  in  geri-
tric  patients  with  ESRD  who  underwent  hip  fracture  surgery
nder  spinal  anesthesia.
aterials and methods
his  study  was  approved  by  the  Baskent  University  Insti-
utional  Review  Board  and  Ethics  Committee  (Project  no:
A12/166).  After  obtaining  written  informed  consent  from
he  patients,  60  elderly  patients  (age  ≥  65  years)  with  end
tage  renal  failure  on  dialysis  treatment  (glomerular  ﬁl-
ration  rate  <  15,  Stage  5)  and  hip  fracture  scheduled  for
nterograde  femoral  intramedullary  nailing  were  included  in
his  double-blind,  randomized,  controlled  study.  Exclusion
riteria  were  decompensated  respiratory  or  heart  failure,ers,  cognitive  disorders,  language  problems,  patients  with
 contraindication  for  regional  anesthesia  (coagulopathy,
istory  of  anticoagulant  use,  spinal  cord  disease  and  patients
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ho  rejected  spinal  anesthesia)  and  history  of  allergy  to  any
edications  used  in  this  study.
The  randomization  scheme  was  developed  by  a  com-
uter  and  covered  in  sealed  envelopes.  These  envelopes
ere  prepared  by  an  independent  anesthesiologist  who  was
ot  associated  with  the  study.  The  envelopes  were  opened
y  the  anesthesia  technician,  who  also  prepared  the  study
rugs.
Patients  were  randomly  divided  into  two  groups:
Group  control  (Group  C):  Saline  infusion  for  premedi-
cation,  midazolam  0.02  mg/kg;  spinal  block  (hyperbaric
bupivacaine  0.5%,  12.5  mg,  n  = 30).
Group  DEX  (Group  D):  0.5  g/kg/10  min  dexmedetomidine
infusion  for  premedication,  midazolam  0.02  mg/kg;  spinal
block  (hyperbaric  bupivacaine  0.5%,  12.5  mg,  n  =  30).
The  study  drugs  were  brought  to  the  operation  the-
ter  by  the  anesthesia  technician.  The  anesthesiologist  who
erformed  premedications,  spinal  anesthesia,  intraopera-
ive  postoperative  follow-ups  and  data  recordings  was  also
linded  to  the  study  drugs  and  group  allocation.
A  peripheral  intravenous  line  was  placed  using  an  18--20
auge  catheter  in  patients.  Patients  arrived  in  the  oper-
tion  theater  without  premedication.  Routine  anesthesia
onitoring  was  performed  with  pulse-oxymeter,  5-lead  ECG,
oninvasive  blood  pressure  measurement,  pulse  oxymetry
nd  BIS.  BIS  scores  were  measured  using  an  Aspect  BIS  Vista
onitor  (Aspect  Medical  Systems,  Inc).  Electroencefalogram
EEG)  was  recorded  using  BIS  QUATROTM sensor  stuck  to  the
repared  forehead  skin  as  explained  in  the  instructions.  All
he  patients  received  0.02  mg/kg  midazolam.  0.5  g/kg  DEX
n  20  mL  was  administered  in  10  min  with  an  infusion  pump.
n  equivalent  volume  of  saline  solution  was  given  to  the
ontrol  group  by  using  the  same  method.  Baseline,  1-,  5-,
0-minute  OAA/S  scores,  BIS,  peripheral  oxygen  saturation
SpO2),  heart  rate  (HR),  systolic  blood  pressure  (SBP),  dias-
olic  blood  pressure  (DBP)  values  were  recorded.  At  this
eriod  250  mL  of  0.9%  NaCl  was  infused.  Basal  SBP,  DBP,
R,  SpO2,  BIS  values  were  recorded  before  induction  of
he  spinal  block.  Lumbar  puncture  was  performed  in  lateral
ecubitis  position  with  a  Quincke® 27  gauge  spinal  nee-
le  at  the  L3--L4  interspaces  using  the  midline  approach.
atients  were  promptly  rotated  to  supine  position  after
f
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Table  1  The  observer’s  assessment  of  alertness/sedation  score.
Responsiveness  Speech  Fac
Responds  readily  to  name  spoken
in  normal  tone
Normal  Nor
Lethargic response  to  name
spoken  in  normal  tone
Mild  slowing  or
thickening
Mil
Responds  only  after  name  is  called
loudly/or  repeatedly
Slurring  or  prominent
slowing
Ma
(sla
Responds only  after  mild  prodding
or shaking
Few  recognizable
words
--  
Does not  respond  to  mild  prodding
or shaking
--  --  P.  Ergenoglu  et  al.
lock  induction.  Induction  of  the  spinal  block  was  accepted
s  time  of  0  for  all  intraoperative  data  recordings.  All  param-
ters  were  recorded  at  1-,  5-  min  and  every  5  min  for  the
rst  hour  and  following  the  ﬁrst  hour  every  15  min  during
urgery.
Hypotension  was  described  as  ≥25%  decrease  in  SBP
rom  the  baseline  or  in  cases  when  systolic  blood  pressure
ecreases  below  90  mmHg.  Ephedrine  5  mg  was  adminis-
ered  intravenously  and  the  rate  of  crystalloid  infusion  was
ncreased.
The  sensorial  block  level  and  the  motor  block  level  were
ssessed  by  pinprick  test  and  modiﬁed  Bromage  scale  (0  =  no
otor  block,  1  =  hip  ﬂexion  with  extended  leg  blocked,
 =  knee  ﬂexion  blocked,  3  =  complete  motor  block),  respec-
ively.  Time  to  reach  the  level  of  T10  and  to  Bromage  3  was
lso  noted.  Propofol  infusion  was  started  in  all  the  patients
t  a  dose  of  50  mcg/kg/min  after  the  level  of  block  arised
o  T10  dermatome  level.  OAA/S  scale  was  used  for  evalu-
ting  the  level  of  sedation16 (Table  1).  Intermittent  0.5  mL
olus  doses  of  propofol  were  given  for  reaching  to  target
AA/S  scores  and  BIS  levels  at  the  beginning  of  the  seda-
ion  if  necessary.  Sedative  agent  (DEX  vs  propofol)  infusion
tarting  time  was  accepted  as  0  point  for  the  recording  of
he  time  to  reach  to  OAA/S  score  4  and  the  time  to  reach  to
IS  ≤  80.  Target  BIS  values  were  between  70  and  80.  Infusion
ate  was  titrated  according  to  the  targeted  OAA/S  scores
nd  BIS  levels.  In  case  OAA/S  score  <  4  and  BIS  <  70,  propofol
nfusion  rate  was  reduced.  Propofol  infusion  was  stopped  at
he  beginning  of  skin  suturing.
Patients  were  monitored  at  the  postoperative  care  unit
nd  all  monitoring  parameters  were  registered  at  every
 min  for  1  h.  Criteria  for  transferring  the  ward  were
AA/S  =  5,  BIS  >  90,  Bromage  =  0--1.
Total  propofol  consumption,  time  necessary  to  reach  the
argeted  level  of  sedation  (OAA/S  score  4  and  BIS  ≤  80),
ropofol  dose  required  for  targeted  OAA/S  score  and  BIS
evels,  recovery  time  (BIS  >  90),  duration  of  surgery,  amount
f  bleeding,  vasoactive  drug  need  were  recorded.  Pos-
ible  side  effects  and  possible  complications  during  the
reoperative,  intraoperative  period  and  the  postoperative
ollow-up  such  as  hypotension  (SBP  <  90  mmHg),  bradycardia
HR  <  60  min),  respiratory  depression  (SpO2 ≤  90%),  nausea,
omiting,  and  deep  sedation  were  carefully  monitored  and
ecorded.
ial  expression  Eyes  Composite  score
mal  Clear;  no  ptosis  5  (alert)
d  relaxation  Glazed  or  mild  ptosis
(less  than  half  the
eye)
4
rked  relaxation
ck  jaw)
Glazed  or  marked
ptosis  (half  the  eye  or
more)
3
--  2
--  1
329
Table  2  Demographic  data  and  block  characteristics.
Group  C  Group  D
Age  (yr)  71.70  ±  4.84  70.83  ±  5.18
Height (cm)  163.73  ±  5.89  163.96  ±  5.34
Weight (kg)  64.76  ±  7.02  64.40  ±  6.01
Duration  of  surgery  (min)  103.63  ±  7.77  102.56  ±  6.40
Time to  reach  to  T10
(min)
3.63  ±  0.55  3.60  ±  0.53
Time to  reach  to
Bromage  3  (min)
4.63  ±  0.56  4.56  ±  0.54
Time to  reach  to 180.0  ±  8.51 181.16  ±  7.27
s
C
e
l
t
w
m
t
p
(
mDexmedetomidine  premedication  on  geriatric  patients  
Statistical analysis
Statistical  analysis  was  performed  using  the  statistical  pack-
age  SPSS  (Version  17.0,  SPSS  Inc.,  Chicago,  IL,  USA).  The
primary  outcome  of  this  study  was  total  propofol  con-
sumption  during  the  hip  fracture  surgery.  A  power  analysis
indicated  that  26  patients  per  group  were  required  to  detect
a  true  difference  of  40  mg  between  groups  where  the  antici-
pated  standard  deviation  was  43.16.  The  standard  deviation
was  based  on  a  pilot  group  of  patients  undergoing  hip  frac-
ture  surgery.  The  type  1  error  was  set  at  0.05  and  type
II  error  at  0.10.  We  allowed  for  4  more  patients  in  each
groups  to  compensate  for  drop  outs  during  the  study  period.
For  each  continuous  variable,  normality  was  checked  by
Kolmogorov--Smirnov  and  Shapiro--Wilk  tests  and  by  his-
tograms.  Independent  samples  t-test  and  the  Mann--Whitney
U-test  were  performed  for  between-groups  comparisons
where  appropriate.  Pre-post  measures  were  analyzed  by
Repeated  Measure  Analyses.  Values  of  p  <  0.05  were  consid-
ered  to  be  statistically  signiﬁcant.
Results
Sixty-hemodialysis  dependent  chronic  renal  failure  patient
scheduled  for  hip  fracture  repair  were  enrolled  in  the  study.
Fig.  1  presents  the  allocation  of  patients  in  groups.  The
groups  were  comparable  with  respect  to  demographic  data,
duration  of  surgery,  time  to  reach  to  T10,  to  Bromage  3  and
to  Bromage  0  (Table  2).
Total  propofol  consumption,  propofol  dose  required
for  targeted  sedation  levels  and  recovery  time  were
m
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Allocated to Dexmedetomidine group (n=30)
♦ Received allocated intervention (n=30)
♦ Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
♦ Excluded from analysis (n=0)
Analysed (n=30)
Figure  1  StudyBromage  0  (min)
Data expressed as mean ± SD.
igniﬁcantly  lower  in  Group  D  when  compared  with  Group
 (p  <  0.001).  The  time  to  achieve  to  targeted  sedation  lev-
ls  according  to  OAA/S  score  and  BIS  levels  was  signiﬁcantly
ower  in  Group  C  compared  with  Group  D  (p  <  0.001).  All
he  patients  in  Group  D  achieved  targeted  sedation  levels
ith  only  DEX  infusion  without  propofol  infusion  require-
ent  (Table  3).
Comparison  of  preoperative  OAA/S  and  BIS  scores  showed
hat  the  scores  were  signiﬁcantly  lower  in  Group  D  com-
ared  with  Group  C  at  preoperative  5th  and  10th  minutes
p  <  0.001).  Intraoperative  OAA/S  scores  at  1-,  3-,  5-,  10th
inutes  and  intraoperative  BIS  scores  at  1-,  3-,  5-,  10-,  15th
inutes  were  signiﬁcantly  lower  in  Group  D  compared  with
roup  C  (p  <  0.05).  The  scores  were  similar  in  both  groups
ill  75th  minutes  and  were  signiﬁcantly  lower  at  75th,  90th
inutes  in  group  C  (p  <  0.05)  (Figs.  2  and  3).  Postoperative
ized (n=60)
ion
-Up
sis
eligibility (n=60)
Excluded (n=0)
Allocated to control group (n=30)
♦ Not meeting inclusion criteria (n=0)
♦ Declined to participate (n=0)
♦ Other reasons (n=0)
♦ Received allocated intervention (n=30)
♦ Did not receive allocated intervention (n=0)
♦ Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analysed (n=30)
 ﬂow  chart.
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Figure  2  BIS  values  of  the  patients.  Values  given  
Table  3  Sedation  data.
Group  C  Group  D  p
Time  to  achieve
BIS  ≤  80  (min)
5.08  ±  0.51  7.65  ±  1.49  <0.001
Time to  reach  to
OAA/S  score  4
(min)
4.03  ±  0.45  5.28  ±  0.85  <0.001
Propofol  dose  for
BIS  ≤  80  (mg)
37.17  ±  5.83  0.00  ±  0.00  <0.001
Total propofol
consumption  (mg)
197.0  ±  50.08  82.0  ±  23.03  <0.001
Recovery  time 16.73  ±  1.84  7.30  ±  1.52  <0.001
O
o
m
g
D
g
a
i
t
n
r
D
I
c
t
t
O
e
w
(
(
5
m
n
a
s
p
i
b
a
a
d
u
chronic  renal  failure  have  demonstrated  that  the  drug
F
P(BIS  ≥  90)  (min)
Data expressed as mean ± SD.
AA/S  scores  were  similar  between  groups  (Fig.  3).  Post-
perative  BIS  scores  were  signiﬁcantly  lower  at  5-,  10th
inutes  in  Group  C  (p  <  0.001);  but  was  similar  between
roups  after  the  10th  minutes  (Fig.  2).
The  heart  rate,  SBP,  DBP,  SpO2 showed  decrease  at  Group
 but  there  were  no  signiﬁcant  differences  among  two
roups.  Hypotension  was  observed  at  8  patients  in  Group  D
nd  9  patients  in  Group  C;  bradycardia  observed  at  6  patients
n  Group  D  and  5  patients  in  Group  C  during  the  intraopera-
ive  period.  However  the  difference  between  the  groups  was
ot  statistically  signiﬁcant.  None  of  the  patients  exhibited
espiratory  depression,  nausea  and  vomiting.
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igure  3  OAA/S  scores  of  the  patients.  Values  given  are  median  
O, postoperative.are  median  (*p  <  0.001; †p  =  0.001; ‡p  =  0.002).
iscussion
n  this  study  we  showed  that  in  geriatric  patients  with
hronic  renal  failure  sedation  regimen  with  DEX  premedica-
ion  reduces  total  propofol  consumption  with  rapid  recovery
ime  (Group  C:  16.73  ±  1.84  min;  Group  D:  7.30  ±  1.52  min).
n  the  other  hand,  according  to  the  pharmacokinetic  prop-
rties  the  time  required  to  attain  the  aimed  level  of  sedation
as  signiﬁcantly  shorter  with  propofol  in  the  control  group
5.08  ±  0.51  min)  in  comparison  with  the  DEX  premedication
7.65  ±  1.49  min).
Propofol  is  an  ultrafast  agent  with  a  peak  effect  within
 min  of  administration  and  is  used  for  sedation  or  anesthesia
aintenance.17,18 It  has  been  reported  that  the  pharmacoki-
etics  of  bolus  or  infusion  doses  are  not  affected  markedly
nd  can  be  used  safely  in  ESRD  patients.19,20 DEX  is  a  highly
elective  2 adrenoceptor  agonist  drug  with  sedative,  sym-
atholytic,  and  analgesic  actions.  It  is  metabolized  into  its
nactive  metabolites  in  liver  and  its  elimination  is  unaffected
y  renal  disease.  By  virtue  of  these  properties,  it  may  offer
n  alternative  option  for  sedation  in  ESRD  patients.15,21 It  has
lso  been  reported  that  it  does  not  exert  any  respiratory
epressant  effect  even  in  high  doses,  and  it  can  be  safely
sed  for  sedation  in  very  elderly  people.22
Dose  determination  studies  for  DEX  in  patients  withrovided  sufﬁcient  sedation  with  any  signiﬁcant  side  effect
t  a  dose  of  0.6  g/kg/10  min  in  volunteer  patients  aged
8  to  65  years  with  creatinine  clearance  of  <30.15 We  also
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1Dexmedetomidine  premedication  on  geriatric  patients  
attained  the  desired  sedation  level  without  any  signiﬁcant
hemodynamic  response  or  side  effect  with  similar  premed-
ication  doses  of  DEX  (0.5  gr/kg/10  min).  Also  we  observed
that  all  the  patients  in  Group  D  reached  targeted  sedation
levels  following  preoperative  DEX  infusion  without  any
propofol  requirement.
It  has  been  reported  that  DEX  used  as  an  additive  agent
decreases  propofol  consumption.23 Also  in  our  study  a  propo-
fol  dose  titration  was  performed  after  DEX  premedication  for
sedation  with  the  guidance  of  OAA/S  and  BIS  monitoring.  It
was  demonstrated  that  propofol  consumption  was  2.4-fold
greater  than  the  study  group  (197.0  mg  vs  82.0  mg)  and  thus
the  recovery  period  was  2.29  times  longer  in  the  control
group  (16.73  min  vs  7.30  min).  According  to  these  results,  it
may  be  suggested  that  the  lower  OAA/S  and  BIS  scores  at
75  and  90  min  at  the  intraoperative  period  as  well  as  lower
BIS  scores  and  a  signiﬁcantly  longer  recovery  time  at  5  and
10  min  at  the  postoperative  period  observed  in  the  control
group  were  associated  with  a  higher  propofol  consumption,
and  thus  dexmedetomidine  had  an  important  effect  on  post-
operative  early  recovery.
One  other  parameter  that  should  be  taken  into  con-
sideration  is  the  hemodynamic  response.  In  addition  to
sympatholytic  effects  of  spinal  anesthesia,  an  additive  inter-
action  with  cardiovascular  effects  of  DEX  and  propofol  may
be  possible.  DEX  is  known  to  have  some  cardiovascular
effects  including  hypotension  and  bradycardia  owing  to  its
sympatholytic  effects.  However,  it  has  been  reported  that
it  offers  a  good  cardiovascular  stability  and  thus  it  is  a  good
sedative  agent.24,25
In  a  study  comparing  sedation  application  with
dexmedetomidine  or  midazolam  in  ESRD  patients  it  was
reported  that  none  of  the  patients  experienced  prolonged
hypotension  or  bradycardia,  all  responded  satisfactorily  to
the  treatment,  and  none  of  them  were  excluded  from  the
study  even  with  large  loading  doses  of  1  g/kg/10  min  of
dex.14 We  also  did  not  demonstrate  a  signiﬁcantly  different
hemodynamic  response  to  DEX  loaded  at  a  dose  of  0.5  g/kg
compared  to  the  control  group.  However,  both  groups
developed  intraoperative  hypotension  (Group  C,  30%;  Group
D,  26.7%)  and  bradycardia  (Group  C,  16.7%;  Group  D,
20%)  after  propofol  infusion,  which  quickly  resolved  upon
administration  of  sympathomimetics.  This  response  may  be
an  additive  result  of  the  venodilatative  effect  of  propofol
and  the  sympatholytic  effect  of  spinal  anesthesia  rather
than  the  effect  of  DEX.
In  the  present  study  we  found  that  premedication  with
DEX  at  a  dose  of  0.5  g/kg  for  10  min  attained  sufﬁcient
and  aimed  sedation  levels  without  propofol  requirement
during  the  preoperative  period.  DEX  premedication  also
reduced  intraoperative  propofol  consumption,  signiﬁcantly
promoted  early  recovery  and  was  not  the  cause  of  severe
side  effects.  In  conclusion,  we  believe  that  low  dose  DEX
premedication  in  addition  to  propofol  infusion  might  be  an
alternative  regimen  in  geriatric  patients  with  ESRD  for  seda-
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